ArticleJournal for immunotherapy of cancer2021

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).

Marijo Bilusic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.